Skip to main content
. Author manuscript; available in PMC: 2020 Oct 6.
Published in final edited form as: Mol Carcinog. 2019 Jun 10;58(10):1770–1782. doi: 10.1002/mc.23064

Figure 1. Olaparib resistant high grade serous ovarian cancer cells have increased Wnt activation.

Figure 1.

A) PEO1 (TP53 and BRCA2-mutated) were treated in a step-wise fashion with increasing doses of olaparib. PEO1 sensitive and resistant (PEO1-OR) cells were plated in a 24-well plate and treated with increasing doses of olaparib for 12 days. Cells were stained with crystal violet. B) Four clonal olaparib resistant populations were established and olaparib resistance was confirmed with a dose response colony formation assay. Dose response curves are graphed and IC50 with 95% confidence interval indicated. C) PEO1 and PEO1-OR were transfected with TCF transcriptional reporter (TOP-FLASH) or a control reporter (FOP-FLASH). Luciferase activity was measured. D) RNA from PEO1 and PEO1-OR was extracted and utilized for a quantitative reverse-transcriptase PCR (qRT-PCR) against CCND1, FOSL1, WNT3A, WNT7B, WNT5A, and SFRP1. Beta-2-microglobulin (B2M) was used as an internal control. Experiments performed in triplicate. Statistical test used to calculate p-values, unpaired two-tailed t-test. Error bars = SEM.